(E)-1-<4-(dimethylamino)phenyl>-3-methyl-1-butene

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-1-<4-(dimethylamino)phenyl>-3-methyl-1-butene
• 英文别名: N,N-dimethyl-4-[(E)-3-methylbut-1-enyl]aniline
• 化学式: C₁₃H₁₉N
• 分子量: 189.301
• InChiKey: AUQGKTBBAKRAKX-AATRIKPKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  (E)-1-<4-(dimethylamino)phenyl>-3-methyl-1-butene 在 四氧化锇 、 N-甲基吗啉氧化物 、 三乙胺 作用下， 以 四氢呋喃 、 水 、 丙酮 、 甲苯 、 叔丁醇 为溶剂， 反应 22.5h， 生成 (+/-)-trans-4-<(dimethylamino)phenyl>-5-isopropyl-1,3-dioxolan-2-one
  参考文献：
  名称：

  Cyclocondensation of oxalyl chloride with 1,2-glycols

  摘要：

  Oxalyl chloride reacts with a wide range of acyclic 1,2-glycols 1 in the presence of triethylamine to produce 1,3-dioxolan-2-ones 3 together with 1,4-dioxane-2,3-diones 2. Ethylene glycol (1d), monosubstituted ethylene glycols 1e, j-1, and erythro-1,2-disubstituted ethylene glycols 1f, m,o provide the cyclic carbonates 3 as the minor products, while the threo-compounds 1g, i, n,p,q and pinacol (1h) afford 3 as the main products. The formation of 3 may be rationalized in terms of stereoelectronically controlled cleavage of the conjugate base 17- of the tetrahedral intermediates. The rate for the conformational change of 17- into 18- and the equilibrium constant between these conformers are proposed to be the major factors affecting the reaction pattern.

  DOI：

  10.1016/s0040-4020(01)81546-5
• 作为产物：
  描述：

  在 二苯二硫醚 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 (E)-1-<4-(dimethylamino)phenyl>-3-methyl-1-butene
  参考文献：
  名称：

  Cyclocondensation of oxalyl chloride with 1,2-glycols

  摘要：

  Oxalyl chloride reacts with a wide range of acyclic 1,2-glycols 1 in the presence of triethylamine to produce 1,3-dioxolan-2-ones 3 together with 1,4-dioxane-2,3-diones 2. Ethylene glycol (1d), monosubstituted ethylene glycols 1e, j-1, and erythro-1,2-disubstituted ethylene glycols 1f, m,o provide the cyclic carbonates 3 as the minor products, while the threo-compounds 1g, i, n,p,q and pinacol (1h) afford 3 as the main products. The formation of 3 may be rationalized in terms of stereoelectronically controlled cleavage of the conjugate base 17- of the tetrahedral intermediates. The rate for the conformational change of 17- into 18- and the equilibrium constant between these conformers are proposed to be the major factors affecting the reaction pattern.

  DOI：

  10.1016/s0040-4020(01)81546-5

文献信息

• Substituted Fused Pyrimidinones and Dihydropyrimidinones
  申请人：FRACKENPOHL Jens

  公开号：US20120157306A1

  公开（公告）日：2012-06-21

  The use of substituted fused pyrimidinones and dihydropyrimidinones of the formula (I) or salts thereof where the radicals of the formula (I) are each as defined in the description, for enhancing stress tolerance in plants to abiotic stress, and for invigorating plant growth and/or for increasing plant yield.

  使用公式（I）中定义的基团的取代融合嘧啶酮和二氢嘧啶酮或其盐，用于增强植物对非生物胁迫的耐受性，激发植物生长和/或增加植物产量。
• SUBSTITUTED FUSED PYRIMIDINONES AND DIHYDROPYRIMIDINONES
  申请人：BAYER INTELLECTUAL PROPERTY GMBH

  公开号：US20150173359A1

  公开（公告）日：2015-06-25

  The use of substituted fused pyrimidinones and dihydropyrimidinones of the formula (I) or salts thereof where the radicals of the formula (I) are each as defined in the description, for enhancing stress tolerance in plants to abiotic stress, and for invigorating plant growth and/or for increasing plant yield.

  使用式(I)中的替代融合嘧啶酮和二氢嘧啶酮或其盐，其中式(I)的基团如描述中所定义，用于增强植物对非生物胁迫的耐受性，促进植物生长和/或增加植物产量。
• Novel Five-Membered Iminocyclitol Derivatives as Selective and Potent Glycosidase Inhibitors: New Structures for Antivirals and Osteoarthritis Therapeutics
  申请人：Liang Pi-Hui

  公开号：US20090306174A1

  公开（公告）日：2009-12-10

  Novel 5-membered iminocyclitol derivatives were found to be a potent and selective inhibitors of the glycoprotein processing α- and β-glucosidase which were further found to be active antiviral agents against Japanese encephalitis virus, dengue virus serotype 2 (DEN-2), human SARS coronavirus and human β-hexosaminidase, a new target for development of osteoarthritis therapeutics.
• PROTEIN SECRETION INHIBITORS
  申请人：KEZAR LIFE SCIENCES

  公开号：US20220153732A1

  公开（公告）日：2022-05-19

  Provided herein are secretion inhibitors, such as inhibitors of Sec61, methods for their preparation, related pharmaceutical compositions, and methods for using the same, wherein the compound has a structure of Formula (I), (II), or (III).
• US7919521B2
  申请人：——

  公开号：US7919521B2

  公开（公告）日：2011-04-05